{ "@context": "https://orbyd.app/schemas/dossier.v1.json", "ticker": "ERAS", "name": "Erasca, Inc.", "url": "https://orbyd.app/dossiers/ERAS/", "json_url": "https://orbyd.app/dossiers/ERAS.json", "status": "DORMANT", "current_conviction": "LOW", "graded_conviction": null, "archetype": { "code": "a5", "n": 5 }, "current_thesis": "Post-crash story reset: 2026-07-13 updated ERAS-0015 Phase 1 data (57% uORR at 32 mg in 2L+ KRAS G12X pancreatic, n=7) plus 2027 pivotal plans, immediately monetised via a 31,428,572-share offering at $17.50 on 2026-07-14. Funded, but the next data cut is guided to H1 2027 — the near-term dated events are the 2026-08-10 class-action lead-plaintiff deadline and an unresolved RevMed patent claim.", "invalidation_trigger": "A weekly close below $16 (surrenders the 2026-06-26 recovery shelf and leaves the $17.50 July offering price overhead); secondarily, a filed Revolution Medicines infringement suit or injunction motion naming ERAS-0015, or the H1-2027 data guidance slipping further with no dated ERAS-4001 readout.", "catalyst_date": "2026-08-10", "outcome": "OPEN", "outcome_date": null, "invalidation_fired": null, "themes": [ "oncology-immunology", "binary-catalyst-biotech" ], "tags": [], "sources": [], "notes": [ "No product revenue: valuation is entirely pipeline-discounted, so financing terms and share issuance are recurring inputs to the equity story.", "Efficacy figures are UNCONFIRMED response rates from small dose-escalation cohorts (n=7 at the 32 mg dose); confirmation and larger cohorts can move them materially.", "Lead asset ERAS-0015 carries an unresolved third-party allegation of infringing U.S. Patent 12,409,225, with no adjudication date disclosed.", "Cash runway 'into H2 2028' was guided on 2026-05-12, before the July raise; post-offering runway has not been restated in the material reviewed.", "The April 2026 dataset included a treatment-related Grade-5 pneumonitis death disclosed on the earnings call rather than in the press release." ], "body_markdown": "## Current Thesis\n- The leg an investor is buying has changed shape since April. What was a wrecked post-crash recovery trade is now a funded, pivotal-bound pan-RAS story: on 2026-07-13 Erasca published updated AURORAS-1 Phase 1 data for ERAS-0015 and laid out registration-enabling plans, and on 2026-07-14 it priced an upsized offering of 31,428,572 shares at $17.50 (~$550M gross) — equity sold one day after the data.\n- The updated numbers were credible but narrow: 57% unconfirmed ORR at the 32 mg recommended dose in 2L+ KRAS G12X pancreatic cancer (n=7), median relative dose intensity 100% at both 24 mg and 32 mg, 6 of 7 patients at 32 mg and 6 of 8 at 24 mg still on treatment, no DLTs at the monotherapy recommended doses and no discontinuations attributed to treatment-related adverse events (2026-07-13 release).\n- The problem is the calendar. The 2026-07-13 plan puts the registration-enabling 2L+ NSCLC trial in H1 2027, a Phase 3 in 1L pancreatic in 2027, a Phase 3 in RAS-mutant NSCLC in H2 2027–H1 2028, and the next monotherapy/combination data cut in H1 2027. Between now and then the dated events are legal and financial, not clinical.\n- Life-cycle: **MATURING**, late in that phase. Attention expanded and was monetised (2026-07-13/14), sell-side re-marked to neutral stances with targets that bracket the tape (BofA Neutral $18 on 2026-07-14; Morgan Stanley Equal-Weight $21 on 2026-07-20), and the last dated company news is three weeks old. Price closed $18.41 on 2026-08-07, 18.1% under the $22.47 52-week high, RSI(14) 46.3 — working, not extending.\n\n## Bull Case\n- (data) The 2026-07-13 cut added patients and follow-up to the April dataset and held up on the dimension that usually breaks early pan-RAS assets: tolerability. Median relative dose intensity 100% at 24 mg and 32 mg, low interruption/reduction rates, no treatment-related discontinuations. Dose intensity at 100% in a pancreatic population is the datapoint that makes combination and 1L ambitions plausible.\n- (data) April's efficacy anchor stands: 62% unconfirmed ORR in 2L+ KRAS G12X NSCLC and 75% in post-ICI/platinum patients (2026-04-27), which is what put the asset into the same conversation as Revolution Medicines' RMC-6236.\n- (combination) ERAS-0015 16 mg with panitumumab in metastatic colorectal cancer cleared its cohort with no DLTs in 4 evaluable patients, escalation ongoing at 24 mg (2026-07-13) — a second indication path that does not depend on monotherapy depth.\n- (balance sheet) Cash, equivalents and marketable securities were $408.5M at 2026-03-31 versus $341.8M at 2025-12-31, with runway then guided into H2 2028 (Q1 2026 results, 2026-05-12). The July raise of ~$550M gross is additive to that base and lands before, not during, the Phase 3 spend.\n- (sell-side direction) Targets moved up twice post-data: BofA to $18 (2026-07-14), Morgan Stanley to $21 (2026-07-20). Both raises came from firms holding non-buy ratings, so the move was to valuation, not to conviction.\n\n## Bear Case\n- (issuance into strength) The company announced a $500M offering on 2026-07-13 and priced it upsized at $17.50 the next day. Roughly 31.4M new shares were placed at a price the stock is now only modestly above. That deal price is the reference the tape is trading against, and the 52-week high of $22.47 sits 18.1% above the 2026-08-07 close.\n- (legal, unresolved) The Revolution Medicines allegation disclosed in the 2026-04-27 8-K — infringement of U.S. Patent No. 12,409,225 plus trade-secret claims tied to preclinical comparisons against RMC-6236 — has no adjudication date attached in any public reporting reviewed. Shares closed $19.50 on 2026-04-27, down 10.71%, on that disclosure, before the far larger next-session decline.\n- (legal, ongoing) The securities class action in S.D. Cal. Covers a 2025-01-14 to 2026-04-26 class period with a lead-plaintiff deadline of 2026-08-10. Plaintiff-firm notices dated 2026-07-30, 2026-08-06 and 2026-08-07 are what most of the recent headline flow consists of.\n- (safety history) The April dataset included a treatment-related Grade-5 pneumonitis event (66-year-old pancreatic patient, 24 mg) disclosed on the 2026-04-27 call rather than in the press release. The 2026-07-13 release reported no new Grade-5 or pneumonitis events; that is an absence in a press release, not an updated full safety table.\n- (vacuum) With the next data cut guided to H1 2027, there is no company-controlled clinical catalyst to re-rate against for roughly two quarters. Multiple compression in that window happens without any thesis element being disproved.\n\n## Setup & Price Structure\n- 2026-08-07 close $18.41. 52-week high $22.47; distance from high −18.1%. Three-month return +81.9%, which measures the recovery off the early-May trough, not the post-offering tape. RSI(14) 46.3 — mid-range, no momentum extension and no oversold condition.\n- $17.50 is the structural line: the 2026-07-14 deal price, where roughly 31.4M shares were placed. Trade above it and the deal book is whole; sustained trade below it and the most recent large marginal buyer is offside.\n- $16.01 (2026-06-26 close) is the shelf the June recovery built before the July data and financing. It is the level below which the July re-rate is fully surrendered.\n- Crowding/positioning observables, stated plainly: equity issued into strength one day after positive data; both named post-data ratings are non-buy with targets of $18 and $21 straddling the close; headline flow since 2026-07-20 has been litigation-firm shareholder notices rather than company news; no insider transaction data appears in the material reviewed, so nothing is claimed either way there.\n\n## Catalyst Calendar (next 30 days)\n\n- **2026-08-10** — Lead-plaintiff application deadline, securities class action, S.D. Cal. (class period 2025-01-14 to 2026-04-26). Sets who controls the case and starts the clock on a consolidated amended complaint.\n- **~2026-08-13 (est., unconfirmed)** — Q2 2026 business update and financial results. Q1 2026 was reported 2026-05-12 and Q2 2025 on 2025-08-12; an early-August earnings-preview piece flagged the print as imminent, so this window may already have opened. The checkable item whenever it lands is the post-offering cash balance and whether runway guidance is restated beyond \"into H2 2028.\"\n\n## Elapsed catalysts\n\n- **Undated, H2 2026** — ERAS-4001 (BOREALIS-1) pan-KRAS Phase 1 monotherapy data, guided in the 2026-01-12 milestones release. The 2026-07-13 update covered ERAS-0015 only and restated no ERAS-4001 timing. This is the IP-independent readout, and it remains without a date. *(passed 27d ago)*\n- **Beyond 30 days** — registration-enabling 2L+ NSCLC trial initiation H1 2027; Phase 3 1L pancreatic 2027; Phase 3 RAS-mutant NSCLC H2 2027–H1 2028; next monotherapy/combination data H1 2027 (all 2026-07-13). *(passed 27d ago)*\n\n## What Would Change Our Mind\n- The structure that breaks first is the July financing shelf. Losing $17.50 on a sustained basis says the ~31.4M shares placed on 2026-07-14 are underwater and the data-plus-capital reset did not hold; a weekly close below $16 completes that break by giving back the 2026-06-26 recovery shelf as well, with no dated clinical catalyst before H1 2027 to lean on.\n- On the fundamental side, a filed Revolution Medicines complaint or a preliminary-injunction motion naming ERAS-0015 converts an open-ended letter into a dated legal proceeding against the only asset that matters — that changes the read regardless of price.\n- Upside change of mind: a dated ERAS-4001 BOREALIS-1 readout announced with a specific window, or a Q2/Q3 disclosure pulling the next ERAS-0015 data cut forward from H1 2027, would restore a company-controlled catalyst and re-open the case for the tape above $17.50.\n- If the 2026-08-10 deadline passes and the consolidated complaint adds offering-related claims tied to the July deal, the litigation overhang widens from backward-looking disclosure claims to the capital raise itself.\n\n## Correlation Notes\n- Closest read-across is Revolution Medicines (RVMD): simultaneously the pan-RAS category comparator and the party asserting U.S. Patent 12,409,225. RVMD clinical or legal headlines move ERAS in both directions, and a strong RVMD dataset is a competitive negative and a category positive at once.\n- Second-order pathway comparables are the KRAS G12C franchises at Amgen and Bristol Myers Squibb, which set the commercial ceiling assumption for RAS-mutant NSCLC and pancreatic.\n- As a pre-revenue, ~$5B-scale clinical biotech with no product cash flow, the name carries small-cap biotech beta (XBI) and rate sensitivity; the July financing was executed into an open window, and follow-on supply conditions for the sector are a live input to any further raise.\n- Litigation-driven headline flow is idiosyncratic and uncorrelated to sector tape — the shareholder-notice releases dated 2026-07-30 through 2026-08-07 generate volume without any change in underlying clinical facts.", "first_seen": "2026-04-19", "last_analyzed": "2026-08-08T15:22:39+00:00", "last_synthesized": "2026-08-08", "last_update_source": "watchlist_research", "license": "Content © orbyd. Cite the canonical URL." }